CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits

CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits

A copper chelator known as diacetylbis(N(4)-methylthiosemicarbazonato) copper II (CuATSM), has been reported to be efficacious in multiple transgenic SOD1 models of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder affecting motor neurons. Here we report that we also observed C...

Full description

Bibliographic Details
Main Authors:	Fernando G. Vieira, Theo Hatzipetros, Kenneth Thompson, Andy J. Moreno, Joshua D. Kidd, Valerie R. Tassinari, Beth Levine, Steven Perrin, Alan Gill
Format:	Article
Language:	English
Published:	Elsevier 2017-06-01
Series:	IBRO Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2451830117300080

Similar Items

Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model
by: Michael T.H. Kuo, et al.
Published: (2019-10-01)

Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the Copper-Chaperone-for-SOD
by: Jared R. Williams, et al.
Published: (2016-05-01)

Monte Carlo Evaluation of Dose Enhancement Due to CuATSM or GNP Uptake in Hypoxic Environments with External Beam Radiation
by: Martinez S, et al.
Published: (2020-05-01)

CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1 G93A mice with a C57BL/6 background
by: Jeremy S. Lum, et al.
Published: (2021-09-01)

CuII(atsm) Attenuates Neuroinflammation
by: Xin Yi Choo, et al.
Published: (2018-09-01)

Mechanisms of cardiovascular hypoxia detection by ⁶⁴Cu-ATSM
by: Shaughnessy, Fiona Sarah
Published: (2014)

Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond
by: Sara Nikseresht, et al.
Published: (2020-11-01)

Cellular Uptake of the ATSM−Cu(II) Complex under Hypoxic Conditions
by: Dr. Gulshan R. Walke, et al.
Published: (2021-04-01)

Does the ATSM-Cu(II) Biomarker Integrate into the Human Cellular Copper Cycle?
by: Gulshan R. Walke, et al.
Published: (2019-07-01)

<sup>64</sup>Cu-ATSM and <sup>18</sup>FDG PET uptake and <sup>64</sup>Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
by: Hansen Anders E, et al.
Published: (2012-06-01)

Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET.
by: Tetsuya Tsujikawa, et al.
Published: (2016-01-01)

Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice
by: Fan Li, et al.
Published: (2015-03-01)

Focus on the controversial aspects of 64Cu-ATSM in tumoral hypoxia mapping by PET imaging
by: Mathilde eColombié, et al.
Published: (2015-08-01)

Evaluation of copper-64-ATSM for non-invasive imaging of tumour hypoxia by positron emission
by: Wood, K. A.
Published: (2009)

64Cu-ATSM/64Cu-Cl2 and their relationship to hypoxia in glioblastoma: a preclinical study
by: Elodie A. Pérès, et al.
Published: (2019-12-01)

64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model.
by: Seong Yong Park, et al.
Published: (2015-01-01)

Quantitative Modeling of Tissue Activity Curves of 64Cu-ATSM and Delineation of Tumour Sub-volumes in Treatment Planning
by: Dalah, Entesar Z.
Published: (2010)

ZnII(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism
by: Erin J. McAllum, et al.
Published: (2015-09-01)

Impact of [64Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report
by: Vincenzo Gangemi, et al.
Published: (2019-12-01)

Cardioprotective effects of Cu(II)ATSM in human vascular smooth muscle cells and cardiomyocytes mediated by Nrf2 and DJ-1
by: Salil Srivastava, et al.
Published: (2016-12-01)

Multiple Administrations of 64Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts
by: Yukie Yoshii, et al.
Published: (2018-02-01)

Preclinical Pharmacokinetic and Safety Studies of Copper-Diacetyl-Bis(N4-Methylthiosemicarbazone) (Cu-ATSM): Translational Studies for Internal Radiotherapy
by: Hiroki Matsumoto, et al.
Published: (2019-09-01)

Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.
by: Fernando G Vieira, et al.
Published: (2015-01-01)

Some Properties of an Unmetalled phthalocyanine Obtained by Chance at Low Temperature
by: Mevlüde CANLICA
Published: (2020-10-01)

Micro Regional Heterogeneity of 64Cu-ATSM and 18F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis.
by: Kamilla Westarp Zornhagen, et al.
Published: (2015-01-01)

Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
by: Tengzhi Liu, et al.
Published: (2020-04-01)

Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.
by: Veerle Kersemans, et al.
Published: (2011-01-01)

Controlled administration of penicillamine reduces radiation exposure in critical organs during 64Cu-ATSM internal radiotherapy: a novel strategy for liver protection.
by: Yukie Yoshii, et al.
Published: (2014-01-01)

Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation (18F-FDG, 64Cu-ATSM and 18F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring
by: Kamilla Westarp Zornhagen, et al.
Published: (2015-09-01)

Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model
by: Zhao-Hui Jin, et al.
Published: (2018-06-01)

Confounds in “Failed” Replications
by: Paola Bressan
Published: (2019-09-01)

Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice
by: Kari A. Trumbull, et al.
Published: (2012-01-01)

Failed Replication of Oxytocin Effects on Trust: The Envelope Task Case.
by: Anthony Lane, et al.
Published: (2015-01-01)

Born to fail: flaws in replication design produce intended results
by: Abraham D. Flaxman, et al.
Published: (2020-03-01)

The Reputational Consequences of Failed Replications and Wrongness Admission among Scientists.
by: Adam K Fetterman, et al.
Published: (2015-01-01)

Superoxide Dismutases (SODs) and SOD Mimetics
by: Gloria E. O. Borgstahl, et al.
Published: (2018-11-01)

Modification of episodic memories by novel learning: a failed replication study
by: Kevin van Schie, et al.
Published: (2017-11-01)

Dexpramipexole is ineffective in two models of ALS related neurodegeneration.
by: Fernando G Vieira, et al.
Published: (2014-01-01)

Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice
by: Jessica Nicks, et al.
Published: (2014-10-01)

When Peace Fails But Terrorism Succeeds : Do Failing Peace Agreements Encourage Terrorism?
by: Thompson, Pierre
Published: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lg24lnold04fqf7pf5o4lqbvp1